Skip to main content

Data Submitters

Board of Pharmacy Administrative Rule 338.3162b states all pharmacies, dispensing practitioners, and veterinarians who dispense schedules 2-5 controlled substances are required to electronically report this prescription data to MAPS on a daily basis. The data required by Rule 338.3162b shall be forwarded to the department by the end of the next business day and shall include data for all controlled substances dispensed since the previous transmission or report.

Controlled substance dispensations should be reported to MAPS via the PMP Clearinghouse. To register, please go to https://pmpclearinghouse.net. Please review the Data Submission Dispenser Guide below for additional information.

REPORTING EXEMPTIONS

Reporting exemptions include controlled substances administered to patients, samples of controlled substances provided to a patient, and controlled substances that are dispensed by a physician at a medical institution for a maximum of 48 hours.

A waiver may be requested by dispensers, dispensing practitioners, or veterinarians who do not have the appropriate software to record and report prescription data, which will enable those to submit their prescription data in paper form. Upon approval of the waiver application, a MAPS Claim Form is required to be completed for each controlled substance dispensed and then emailed, faxed, or mailed to MAPS for submission into the database.

Important Documents

Michigan Data Submission Dispenser Guide

Request for Waiver from MAPS Electronic Reporting

MAPS Claim Form

NDC Guidelines

CONTACT MAPS

Telephone: 517-241-0166

Fax: 517-241-5072

Email: BPL-MAPS@michigan.gov

Appriss Health Customer First Center: 1-844-364-4767

MAPS INTEGRATION

The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies until August 31, 2023. Learn how to start the integration process.

MAPS LEGISLATION

If your question(s) pertain to the new opioid legislation, we encourage you to review the recently-released FAQs. Additional questions or concerns can be addressed by contacting MAPS.